Purpose: To evaluate safety and effectiveness of Brolucizumab for Persistent Diabetic Macular Edema
(DME) patients.
Design: Retrospective study.
Method: To report the real-life Brolucizumab therapeutical outcomes with Non-Proliferative Diabetic
Retinopathy (NPDR) with Diabetic macular edema (DME). Materials and Methods: A total of 20 eyes
of 15 patients diagnosed with Non-Proliferative Diabetic Retinopathy (NPDR) with persistent DME
were Retrospective evaluated over a 3-month follow up eyes received a 5-month loading phase scheme.
Study duration was April 2022 to August 2023 at Lions Eye Institute and Hospital and Harun Eye
Foundation Hospital, Dhaka.
The main outcome measures were best-corrected visual acuity (BCVA) in the Snellen chart and central
retinal thickness (CRT) change. In addition, patients were undergone supervision with fluid resolution
in the retina specifically Intra-Retinal Fluid (IRF) and/or Sub-Retinal Fluid (SRF).
Result: A significant improvement of BCVA was observed with 80% of study eyes and 20% of eyes
were not significant. On the other hand, CRT was also within normal limit with 90% study eyes and
10% were not significant.
Conclusion: Brolucizumab is demonstrated to be a safe and efficient alternative in improving both the
anatomical and functional parameters of eyes NPDR with Persistent DME in this small series of
patients.